-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Ucello Therapeutics announced the completion of 160 million yuan in Series A financing, led by Matrix Partners China, Co-Win Ventures, Northern Light Venture Capital) and other companies participated in this round of financing
.
It is understood that Yosano Bio is a new biotechnology company focusing on the development and commercialization of general-purpose cell therapy products.
This round of financing will be mainly used to further improve Yosano Bio's unique "ready-to-use" CAR-T The cell technology platform CBT-X20 is preparing for the Sino-US New Drug Clinical Trial (IND) application of the core product AT19 and the construction of the company's scientific research and production facilities
.
The industry believes that the successful completion of the A round of financing may give Unisino a more solid foundation to challenge the technical bottlenecks encountered in the general-purpose cell therapy industry, and accelerate the development of cells with real clinical value and commercialization potential.
Universal cell therapy product
.
In fact, in recent years, domestic innovative pharmaceutical companies are setting off a wave of financing
.
According to incomplete statistics, in the first half of 2021 alone, the number of IPO pharmaceutical companies on the Science and Technology Innovation Board has reached 23, with a total financing amount exceeding 18 billion yuan
.
Among them, many pharmaceutical companies have raised more than 1 billion yuan
.
It is worth noting that the current time has come to 2022, and this wave of financing is still continuing.
In addition to Yosino Bio, many innovative pharmaceutical companies have recently announced the completion of financing, and the raised funds will be used to accelerate the progress.
Development and production of innovative drugs
.
For example, in January, Zhejiang Shimai Pharmaceutical Co.
, Ltd.
also announced the completion of a new round of financing of several hundred million yuan
.
The funds raised in this round will be mainly used to advance the clinical trials of core products such as class 1 new drug DNV3 (solid tumors and lymphomas), new bispecific antibody drug SMET12 (solid tumors with high EGFR expression), and CMD003 (autoimmune system diseases).
Promote the clinical application of CMD009 (solid tumor), CMD011 (liver cancer), CMDE002 (solid tumor), etc.
and the development of other follow-up pipeline projects, accelerate the launch of drugs, and promote the industrialization process of a series of innovative antibody products
.
Prior to this, Purui Benchmark Technology (Beijing) Co.
, Ltd.
(hereinafter referred to as "Preui Benchmark") has also completed tens of millions of yuan in B+ round financing, which was invested by Suzhou High-tech Venture Capital Group
.
It is reported that this B+ round of financing will help the company to accelerate the upgrade of the AIBERT® (Oncology Multi-omics Data Mining System for New Drug Development) platform, including the computing module (bioinformatics platform) and the experimental module (multi-omics functional laboratory) ) construction
.
In addition, Nanjing Yuxi Pharmaceutical Technology Co.
, Ltd.
(hereinafter referred to as "Yuxi Medicine"), which focuses on the research and development of improved new drugs in the skin field, has also announced the completion of the pre-A round of financing of tens of millions of RMB.
This round of financing was led by Materia Medica.
Friends Capital, Chang Development, Aibo Qingshi and Mingfeng Capital joined the investment, and the original shareholders Yingdi Capital and Tibet Gaoge continued to bless
.
The financing amount will be mainly used for product clinical trials, pipeline research and development, innovative technology platform construction and team replenishment
.
Incomplete statistics show that in January 2022, more than 20 pharmaceutical companies have completed investment in the field of new drugs, and the total financing amount has exceeded 5 billion yuan
.
In this regard, the industry believes that the pharmaceutical industry will continue to set off a "financing wave" in 2022, and as more and more strategic investors pay more attention to the pharmaceutical industry and increase investment, it will also inject more innovation momentum into the pharmaceutical industry.
In order to better promote the emergence and high-quality development of innovative achievements in the pharmaceutical industry
.
.
It is understood that Yosano Bio is a new biotechnology company focusing on the development and commercialization of general-purpose cell therapy products.
This round of financing will be mainly used to further improve Yosano Bio's unique "ready-to-use" CAR-T The cell technology platform CBT-X20 is preparing for the Sino-US New Drug Clinical Trial (IND) application of the core product AT19 and the construction of the company's scientific research and production facilities
.
The industry believes that the successful completion of the A round of financing may give Unisino a more solid foundation to challenge the technical bottlenecks encountered in the general-purpose cell therapy industry, and accelerate the development of cells with real clinical value and commercialization potential.
Universal cell therapy product
.
In fact, in recent years, domestic innovative pharmaceutical companies are setting off a wave of financing
.
According to incomplete statistics, in the first half of 2021 alone, the number of IPO pharmaceutical companies on the Science and Technology Innovation Board has reached 23, with a total financing amount exceeding 18 billion yuan
.
Among them, many pharmaceutical companies have raised more than 1 billion yuan
.
It is worth noting that the current time has come to 2022, and this wave of financing is still continuing.
In addition to Yosino Bio, many innovative pharmaceutical companies have recently announced the completion of financing, and the raised funds will be used to accelerate the progress.
Development and production of innovative drugs
.
For example, in January, Zhejiang Shimai Pharmaceutical Co.
, Ltd.
also announced the completion of a new round of financing of several hundred million yuan
.
The funds raised in this round will be mainly used to advance the clinical trials of core products such as class 1 new drug DNV3 (solid tumors and lymphomas), new bispecific antibody drug SMET12 (solid tumors with high EGFR expression), and CMD003 (autoimmune system diseases).
Promote the clinical application of CMD009 (solid tumor), CMD011 (liver cancer), CMDE002 (solid tumor), etc.
and the development of other follow-up pipeline projects, accelerate the launch of drugs, and promote the industrialization process of a series of innovative antibody products
.
Prior to this, Purui Benchmark Technology (Beijing) Co.
, Ltd.
(hereinafter referred to as "Preui Benchmark") has also completed tens of millions of yuan in B+ round financing, which was invested by Suzhou High-tech Venture Capital Group
.
It is reported that this B+ round of financing will help the company to accelerate the upgrade of the AIBERT® (Oncology Multi-omics Data Mining System for New Drug Development) platform, including the computing module (bioinformatics platform) and the experimental module (multi-omics functional laboratory) ) construction
.
In addition, Nanjing Yuxi Pharmaceutical Technology Co.
, Ltd.
(hereinafter referred to as "Yuxi Medicine"), which focuses on the research and development of improved new drugs in the skin field, has also announced the completion of the pre-A round of financing of tens of millions of RMB.
This round of financing was led by Materia Medica.
Friends Capital, Chang Development, Aibo Qingshi and Mingfeng Capital joined the investment, and the original shareholders Yingdi Capital and Tibet Gaoge continued to bless
.
The financing amount will be mainly used for product clinical trials, pipeline research and development, innovative technology platform construction and team replenishment
.
Incomplete statistics show that in January 2022, more than 20 pharmaceutical companies have completed investment in the field of new drugs, and the total financing amount has exceeded 5 billion yuan
.
In this regard, the industry believes that the pharmaceutical industry will continue to set off a "financing wave" in 2022, and as more and more strategic investors pay more attention to the pharmaceutical industry and increase investment, it will also inject more innovation momentum into the pharmaceutical industry.
In order to better promote the emergence and high-quality development of innovative achievements in the pharmaceutical industry
.
